Edgestream Partners L.P. purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 7,705 shares of the company’s stock, valued at approximately $1,120,000.
Several other institutional investors and hedge funds have also bought and sold shares of MRK. Bullseye Investment Management LLC purchased a new position in Merck & Co., Inc. during the second quarter valued at $27,000. Curry Webb Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $29,000. Horizons Wealth Management purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at about $30,000. Graney & King LLC lifted its position in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares during the period. Finally, Montgomery Financial Services LLC bought a new stake in Merck & Co., Inc. during the second quarter worth about $41,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Recent Merck & Co., Inc. Headlines
Investors following MRK have been watching these headlines:
- Positive Sentiment: A German court overturned an injunction that had restricted Merck from distributing and offering Keytruda SC in Germany. The ruling removes an immediate obstacle to the formulation, although Halozyme says it will pursue a new patent lawsuit. Zacks: HALO Faces Legal Setback in Germany Over MRK's Keytruda SC
- Positive Sentiment: Merck partnered with Isomorphic Labs to discover small-molecule oncology drug candidates, combining the AI drug-design company’s approach with Merck’s data and drug-development expertise. The collaboration could support longer-term growth as Merck prepares for Keytruda’s eventual patent expiry. Business Wire: Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Negative Sentiment: Merck has stopped development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the drug’s benefit-risk profile did not justify continuing. This removes a late-stage blood-cancer candidate from its pipeline. Yahoo Finance: What Does Merck Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
Insider Buying and Selling
Merck & Co., Inc. Stock Up 0.6%
Shares of Merck & Co., Inc. stock opened at $133.56 on Friday. The company has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a price-to-earnings-growth ratio of 6.13 and a beta of 0.13. The company’s 50 day moving average is $145.28 and its 200 day moving average is $129.29. Merck & Co., Inc. has a twelve month low of $95.36 and a twelve month high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the previous year, the firm posted $2.58 EPS. The firm’s revenue was up 4.7% on a year-over-year basis. Research analysts anticipate that Merck & Co., Inc. will post 2.83 EPS for the current year.
Merck & Co., Inc. Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, December 15th will be paid a $0.88 dividend. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. The ex-dividend date is Tuesday, December 15th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 350.52%.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. Barclays upped their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Monday, October 26th. TD Cowen increased their target price on Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, September 23rd. Royal Bank Of Canada reduced their price target on Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a report on Friday, October 30th. Wolfe Research raised their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Finally, Leerink Partners upped their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $155.74.
Get Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Read More
- Five stocks we like better than Merck & Co., Inc.
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
